Inclusion Criteria:  Participants who have a negative screening SARS-CoV-2 rapid antigen test result and who are asymptomatic household contacts with exposure within 96 hours to an individual who is symptomatic and recently tested positive for SARS CoV-2. Fertile participants must agree to use a highly effective method of contraception  Exclusion Criteria:  History of SARS-CoV-2 infection Experiencing measured fever (documented temperature >38˚C or 100.4˚F) or other signs or symptoms consistent with COVID-19 Known medical history of active liver disease Chronic Kidney Disease or have known moderate to severe renal impairment. Known Human Immunodeficiency Virus (HIV) infection with viral load > 400 copies/ml within the last 6 months or taking prohibited medications for HIV treatment Suspected or confirmed concurrent active systemic infection Active cancer, other than localized skin cancer Current or expected use of any medications or substances that are highly dependent on Cytochrome P450 3A4 (CYP3A4) for clearance or are strong inducers of CYP3A4 Has received approved, authorized, or investigational anti-SARS-CoV-2 mAb, convalescent plasma, other drugs for treatment of COVID-19, or other anti-SARS-CoV-2 biologic products Has received or is expected to receive a SARS-CoV-2 vaccine or other approved, authorized, or investigational postexposure prophylaxis treatments during the study period Participating in another interventional clinical study with an investigational compound or device, including those for COVID-19 Known or prior participation in this trial or another trial involving PF-07321332. Females who are pregnant or breastfeeding.